# Study of Niacin in Glioblastoma

> **NCT04677049** · PHASE1,PHASE2 · SUSPENDED · sponsor: **AHS Cancer Control Alberta** · enrollment: 59 (estimated)

## Conditions studied

- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

## Interventions

- **DRUG:** Niacin CRT

## Key facts

- **NCT ID:** NCT04677049
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-03-18
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 59 (ESTIMATED)
- **Why stopped:** Recruitment has been placed on hold to determine evaluability of currently enrolled patients. Recruitment will remain on hold until evaluability is confirmed. If fewer than 48 evaluable patients are achieved, the study will be re-opened to accrual.
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04677049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04677049, "Study of Niacin in Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04677049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*